GlassScriptPhysician profile
William H Clapp
NPI 1912973173
$8,151.22
in general payments reported to CMS, 2019-2025
45 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,361 · 2020: $1,293 · 2021: $1,838 · 2022: $951 · 2023: $1,017 · 2024: $1,194 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,685 · Education: $22.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,684.63 |
| Education | $22.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,184.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $853.52 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $752.62 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $743.36 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $737.46 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $626.26 | 2019-2024 | Ofev, Jardiance |
| Amgen INC. | $620.89 | 2019-2025 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $287.58 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $221.15 | 2019-2021 | |
| Amarin Pharma, INC. | $187.86 | 2020-2022 | |
| Glaxosmithkline, LLC. | $177.95 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $177.26 | 2019-2024 | Camzyos |
| Otsuka America Pharmaceutical, INC. | $154.72 | 2023-2025 | Rexulti, Abilify Maintena |
| Ironshore Pharmaceuticals INC. | $145.03 | 2019-2020 | |
| Lundbeck LLC | $124.64 | 2021-2025 | Vyepti |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Clapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.